Evidence map›Paper›PMID 24646940›Full record

ArticleMucosal immunology2014

Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection.

K Yamamoto, S Nishiumi, L Yang, E Klimatcheva, T Pandina, S Takahashi, H Matsui, M Nakamura, M Zauderer, M Yoshida and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Dysregulation of TNature communications · 2021
    Article
  5. Article
  6. CXCL13 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021
    Review
  7. Gut-resident CX3CR1Science immunology · 2020
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Regulated Production of CXCL13 within the Central Nervous System.Journal of clinical & cellular immunology · 2016
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Targeting CXCL13 During Neuroinflammation.Advances in neuroimmune biology
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

K YamamotoDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
S NishiumiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
L YangDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
E KlimatchevaVaccinex, Inc. 1895 Mount Hope Avenue, Rochester, New York, USA.
T PandinaVaccinex, Inc. 1895 Mount Hope Avenue, Rochester, New York, USA.
S TakahashiThird Department of Internal Medicine, Kyorin University, Tokyo, Japan.
H MatsuiKitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Tokyo, Japan.
M NakamuraGraduate School of Pharmaceutical Science, Kitasato University, Tokyo, Japan.
M ZaudererVaccinex, Inc. 1895 Mount Hope Avenue, Rochester, New York, USA.
M Yoshida1] Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan [2] The Integrated Center for Mass Spectrometry, Graduate School of Medicine, Kobe University, Kobe, Japan [3] Division of Metabolomics Research, Kobe University Graduate School of Medicine, Kobe, Japan.
T AzumaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPVaccinex (United States) · USKitasato Institute Hospital · JPKitasato University · JPKyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter suis infects the stomachs of both animals and humans, and can induce gastric mucosa-associated lymphoid tissue (MALT) lymphomas. It is known that CXC chemokine ligand 13 (CXCL13) is highly expressed in the Helicobacter-infected mice and gastric MALT lymphoma patients, but the pathway that links the activation of CXCL13 and the formation of gastric MALT lymphomas remains unclear. In this study, we examined whether CXCL13 neutralization would interfere with the formation of gastric lymphoid follicles including B cells, CD4+T cells, dendritic cells (DCs), and follicular DCs (FDCs) in germinal centers to determine the role of CXCL13 in the formation of B-cell aggregates after H. suis infection. Moreover, the expression of genes associated with the lymphoid follicle formation was also effectively suppressed by anti-CXCL13 antibody treatment. These results suggest that the upregulation of CXCL13 has an important role in the development of gastric MALT lymphomas and highlight the potential of anti-CXCL13 antibody for protection against Helicobacter-induced gastric diseases.

Indexed as

AnimalsAntibodies, MonoclonalChemokine CXCL13Gastric MucosaGastritisGene Expression RegulationHelicobacter heilmanniiHelicobacter InfectionsLymphoma, B-Cell, Marginal ZoneMicePolymerase Chain ReactionAntibodies, MonoclonalChemokine CXCL13Cxcl13 protein, mouse

Identifiers

PMID24646940
OpenAlexW2033463806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.